BI-1703880
- Generic Name
- BI-1703880
A Study to Test How Different Doses of BI 1703880 in Combination With Ezabenlimab Are Tolerated in People With Different Types of Advanced Cancer (Solid Tumours)
- First Posted Date
- 2022-07-25
- Last Posted Date
- 2025-04-17
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 66
- Registration Number
- NCT05471856
- Locations
- 🇯🇵
Saitama Medical University International Medical Center, Saitama, Hidaka, Japan
🇺🇸Valkyrie Clinical Trials, Los Angeles, California, United States
🇺🇸Yale University School of Medicine, New Haven, Connecticut, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath